Testicular Yolk Sac TumorSymptoms, Doctors, Treatments, Advances & More
Testicular Yolk Sac Tumor Overview
Learn About Testicular Yolk Sac Tumor
St. Vincent Regional Hospital - Cancer Centers Of Montana
Dr. Connor completed an undergraduate degree in Biochemistry at the University of Virginia and later earned her Medical Doctorate at the University of Virginia School of Medicine. She then completed her Obstetrics & Gynecology Residency training at Brown University and Gynecologic Oncology fellowship training at the Cleveland Clinic. She is board-certified in both obstetrics and gynecology and gynecologic oncology. Her clinical interests include preventing, diagnosing, and treating ovarian, uterine, cervical, vaginal and vulvar cancers. Dr. Connor moved to Montana to ensure comprehensive access to gynecologic oncology services in the region.“I care deeply for my patients and work hard for them to have the highest level of care and autonomy in their care.”When not seeing patients, Dr. Connor spends her time with her husband, two children, and two family dogs. They spend most of their time outside, whether skiing, hiking, or catching a soccer game. Dr. Connor is rated as an Advanced provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Bladder Reconstruction.
Jefferson Obstetrics And Gynecology
. Dr. Rosenblum is rated as an Advanced provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Sertoli-Leydig Cell Tumor, Hernia Surgery, and Hysterectomy.
Aurora Gynecologic Oncology
Scott Kamelle is an Oncologist in West Allis, Wisconsin. Dr. Kamelle is rated as an Advanced provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction.
Summary: This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-pr...
Summary: This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish...


